This study is in progress, not accepting new patients
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by David Oh
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- David Oh
I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- PACT Pharma, Inc.
- ID
- NCT03970382
- Phase
- Phase 1 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- At least 21 people participating
- Last Updated